Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Innovent Biologics ( (HK:1801) ).
Innovent Biologics, Inc. has successfully completed the placement of 55,000,000 new shares under its General Mandate, raising approximately HK$4,265.4 million. This strategic move allows the company to continue its growth trajectory by leveraging the General Mandate to issue additional shares, enhancing its financial flexibility and market positioning.
The most recent analyst rating on (HK:1801) stock is a Buy with a HK$65.98 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
More about Innovent Biologics
Innovent Biologics, Inc. is a biotechnology company incorporated in the Cayman Islands, focusing on the development, manufacture, and sale of biologic products. The company is listed on the Hong Kong Stock Exchange under the stock code 1801.
Average Trading Volume: 26,330,143
Technical Sentiment Signal: Buy
Current Market Cap: HK$131B
For an in-depth examination of 1801 stock, go to TipRanks’ Overview page.